1,964 results on '"Owen, Andrew"'
Search Results
152. Precise equilibrium structure of thiazole (c-C3H3NS) from twenty-four isotopologues.
153. Supplementary Figure S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
154. Supplementary Table S1 from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
155. Supplementary Figure Legend from Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies
156. Exosomes as perioperative therapeutics to limit organ injury
157. Millimeter-Wave and High-Resolution Infrared Spectroscopy of 2-Furonitrile─A Highly Polar Substituted Furan
158. Transmissibility of clinically relevant atovaquone-resistantPlasmodium falciparumby anopheline mosquitoes
159. Ex vivo transdermal delivery of 3H-labelled atovaquone solid drug nanoparticles: a comparison of topical, intradermal injection and microneedle assisted administration
160. The Capture Of Eight Montserrat Orioles And Their Subsequent Establishment And Breeding At Jersey Zoo
161. Rapid quantification of low level polymorph content in a solid dose form using transmission Raman spectroscopy
162. Experimental studies of the hypersonic, low density, aerodynamics of re-entry vehicles
163. The role of P-glycoprotein in treatment-resistant epilepsy
164. Species Similarities and Differences in Pharmacokinetics and Distribution of Antiretroviral Drugs
165. Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment
166. Comprehensive quantification of tablets with multiple active pharmaceutical ingredients using transmission Raman spectroscopy—A proof of concept study
167. Use of the learning conversation improves instructor confidence in life support training: An open randomised controlled cross-over trial comparing teaching feedback mechanisms
168. Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies
169. Structured training in assessment increases confidence amongst basic life support instructors
170. Modeling the commute mode share of transit using continuous accessibility to jobs
171. WHO Living Guidelines on antivirals for COVID-19 are evidence-based
172. Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial
173. The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases
174. Prospects for Long-Acting Treatments for Hepatitis C
175. Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment
176. A Holistic Review of the Preclinical Landscape for Long-Acting Anti-infective Drugs Using HIV as a Paradigm
177. Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants
178. Recent advances in pharmaceutical analysis using transmission Raman spectroscopy
179. In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents
180. Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study
181. Special Populations and Pharmacogenetic Issues in Tuberculosis Drug Development and Clinical Research
182. Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial
183. Publish rates of health gain resulting from treatment
184. Monitoring of an esterification reaction by on-line direct liquid sampling mass spectrometry and in-line mid infrared spectrometry with an attenuated total reflectance probe
185. Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study
186. Small bowel resection for ischemia following transcatheter arterial embolization for bleeding jejunal diverticulum: an easily forgotten complication
187. A randomized, open-label trial of combined nitazoxanide and atazanavir/ritonavir for mild to moderate COVID-19
188. PDGFRα/Sca-1 Sorted Mesenchymal Stromal Cells Reduce Liver Injury in Murine Models of Hepatic Ischemia-Reperfusion Injury
189. Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection
190. Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19
191. Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)
192. Mechanisms of Post-critical Illness Cardiovascular Disease
193. Semi-experimental equilibrium (r eSE) and theoretical structures of hydrazoic acid (HN3)
194. Validation and clinical application of a method to quantify efavirenz in cervicovaginal secretions from flocked swabs using liquid chromatography tandem mass spectrometry
195. Device Therapy in Heart Failure
196. Pharmaceutical Nanotechnology: Innovation and Production
197. Developing a Comprehensive U.S. Transit Accessibility Database
198. Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems
199. The effect of two preparation procedures on an equine arena surface in relation to motion of the hoof and metacarpophalangeal joint
200. Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.